<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Shan Z</submitter><funding>Natural Science Foundation of Hubei Province</funding><funding>National Natural Science Foundation of China</funding><pagination>65</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10240765</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(1)</volume><pubmed_abstract>Migraine is the second highest cause of disability worldwide, bringing a huge socioeconomic burden. Improving mitochondrial function has promise as an effective treatment strategy for migraine. Szeto-Schiller peptide (SS-31) is a new mitochondria-targeted tetrapeptide molecule that has been shown to suppress the progression of diseases by restoring mitochondrial function, including renal disease, cardiac disease, and neurodegenerative disease. However, whether SS-31 has a therapeutic effect on migraine remains unclear. The aim of this study is to clarify the treatment of SS-31 for headache and its potential mechanisms. Here we used a mouse model induced by repeated dural infusion of inflammatory soup (IS), and examined roles of Sirt3/Pgc-1α positive feedback loop in headache pathogenesis a</pubmed_abstract><journal>The journal of headache and pain</journal><pubmed_title>SS-31 alleviated nociceptive responses and restored mitochondrial function in a headache mouse model via Sirt3/Pgc-1α positive feedback loop.</pubmed_title><pmcid>PMC10240765</pmcid><funding_grant_id>82101292</funding_grant_id><funding_grant_id>2020CFB226</funding_grant_id><funding_grant_id>81971055</funding_grant_id><funding_grant_id>81801134</funding_grant_id><pubmed_authors>Shan Z</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Xiao Z</pubmed_authors><pubmed_authors>Qiu T</pubmed_authors><pubmed_authors>Liang J</pubmed_authors><pubmed_authors>Hu L</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Zhou Y</pubmed_authors><pubmed_authors>Fan S</pubmed_authors><pubmed_authors>Ding M</pubmed_authors></additional><is_claimable>false</is_claimable><name>SS-31 alleviated nociceptive responses and restored mitochondrial function in a headache mouse model via Sirt3/Pgc-1α positive feedback loop.</name><description>Migraine is the second highest cause of disability worldwide, bringing a huge socioeconomic burden. Improving mitochondrial function has promise as an effective treatment strategy for migraine. Szeto-Schiller peptide (SS-31) is a new mitochondria-targeted tetrapeptide molecule that has been shown to suppress the progression of diseases by restoring mitochondrial function, including renal disease, cardiac disease, and neurodegenerative disease. However, whether SS-31 has a therapeutic effect on migraine remains unclear. The aim of this study is to clarify the treatment of SS-31 for headache and its potential mechanisms. Here we used a mouse model induced by repeated dural infusion of inflammatory soup (IS), and examined roles of Sirt3/Pgc-1α positive feedback loop in headache pathogenesis a</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jun</publication><modification>2025-04-04T14:39:36.364Z</modification><creation>2025-04-04T14:39:36.364Z</creation></dates><accession>S-EPMC10240765</accession><cross_references><pubmed>37271805</pubmed><doi>10.1186/s10194-023-01600-6</doi></cross_references></HashMap>